CN102549007B - 3α-羟基,3β-甲基-5α-孕烷-20-酮(加奈索酮)的制备方法 - Google Patents
3α-羟基,3β-甲基-5α-孕烷-20-酮(加奈索酮)的制备方法 Download PDFInfo
- Publication number
- CN102549007B CN102549007B CN201080035660.3A CN201080035660A CN102549007B CN 102549007 B CN102549007 B CN 102549007B CN 201080035660 A CN201080035660 A CN 201080035660A CN 102549007 B CN102549007 B CN 102549007B
- Authority
- CN
- China
- Prior art keywords
- ganaxolone
- metallic
- organo
- methylating reagent
- ethyl acetate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
- C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
- C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
- C07J7/004—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa
- C07J7/0045—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa not substituted in position 16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23355309P | 2009-08-13 | 2009-08-13 | |
| US61/233,553 | 2009-08-13 | ||
| PCT/US2010/045176 WO2011019821A2 (en) | 2009-08-13 | 2010-08-11 | METHOD FOR MAKING 3α-HYDROXY, 3β- METHYL-5α-PREGNAN-20-ONE (GANAXOLONE) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102549007A CN102549007A (zh) | 2012-07-04 |
| CN102549007B true CN102549007B (zh) | 2015-03-18 |
Family
ID=43586809
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201080035660.3A Active CN102549007B (zh) | 2009-08-13 | 2010-08-11 | 3α-羟基,3β-甲基-5α-孕烷-20-酮(加奈索酮)的制备方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US8362286B2 (enExample) |
| EP (1) | EP2464653B1 (enExample) |
| JP (1) | JP5745517B2 (enExample) |
| KR (1) | KR101778603B1 (enExample) |
| CN (1) | CN102549007B (enExample) |
| AU (1) | AU2010282570B2 (enExample) |
| BR (1) | BR112012003085B1 (enExample) |
| CA (1) | CA2769820C (enExample) |
| EA (1) | EA024269B1 (enExample) |
| ES (1) | ES2524724T3 (enExample) |
| IL (1) | IL217857A (enExample) |
| MX (1) | MX2012001728A (enExample) |
| NZ (1) | NZ597940A (enExample) |
| WO (1) | WO2011019821A2 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX336930B (es) | 2005-11-28 | 2016-02-05 | Marinus Pharmaceuticals | Formulaciones de ganaxolona y metodos para la manufactura y el uso de las mismas. |
| US9629853B2 (en) | 2014-05-21 | 2017-04-25 | Wisconsin Alumni Research Foundation | Uses of ganaxolone |
| CZ2015130A3 (cs) * | 2015-02-25 | 2016-03-30 | Vysoká škola chemicko - technologická v Praze | (3α,5β,20S)-3-Nitrooxy-pregnan-20-karboxylová kyselina |
| MX2018004376A (es) * | 2015-10-16 | 2018-08-01 | Marinus Pharmaceuticals Inc | Formulaciones inyectables de neuroesteroides que contienen nanoparticulas. |
| CN106279326A (zh) * | 2016-08-09 | 2017-01-04 | 南京臣功制药股份有限公司 | 一种醋酸甲羟孕酮胶囊的有关物质及其分析检测方法 |
| CN106366149B (zh) * | 2016-08-09 | 2018-01-23 | 南京臣功制药股份有限公司 | 一种醋酸甲羟孕酮分散片的有关物质及其分析检测方法 |
| KR102518846B1 (ko) | 2016-08-11 | 2023-04-05 | 오비드 테라퓨틱스 인크. | 간질 장애의 치료를 위한 방법 및 조성물 |
| US10391105B2 (en) | 2016-09-09 | 2019-08-27 | Marinus Pharmaceuticals Inc. | Methods of treating certain depressive disorders and delirium tremens |
| IT201800009683A1 (it) * | 2018-10-22 | 2020-04-22 | Ind Chimica Srl | Processo per la preparazione di 3α-idrossi-5α-pregnan-20-one (brexanolone) |
| US11266662B2 (en) | 2018-12-07 | 2022-03-08 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in prophylaxis and treatment of postpartum depression |
| CA3145923A1 (en) | 2019-08-05 | 2021-02-11 | David Czekai | Ganaxolone for use in treatment of status epilepticus |
| AU2020395254A1 (en) | 2019-12-06 | 2022-06-02 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in treating tuberous sclerosis complex |
| IT202000021316A1 (it) | 2020-09-09 | 2022-03-09 | Ind Chimica Srl | PROCESSO PER LA PREPARAZIONE DI (3α,5α)-3-IDROSSI-3-METIL-PREGNAN-20-ONE (GANAXOLONE) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3953429A (en) * | 1970-12-17 | 1976-04-27 | Glaxo Laboratories Limited | Anaesthetic steroids of the androstance and pregnane series |
| US6117994A (en) * | 1994-06-02 | 2000-09-12 | Hoechst Marion Roussel | Intermediates for 16β-methyl steroids |
| WO2007062266A2 (en) * | 2005-11-28 | 2007-05-31 | Marinus Pharmaceuticals | Ganaxolone formulations and methods for the making and use thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5232917A (en) * | 1987-08-25 | 1993-08-03 | University Of Southern California | Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series |
| US5319115A (en) | 1987-08-25 | 1994-06-07 | Cocensys Inc. | Method for making 3α-hydroxy, 3β-substituted-pregnanes |
| DE69435286D1 (de) * | 1993-05-24 | 2010-05-20 | Purdue Pharma Ltd | Verfahren und zusammensetzungen zum hervorrufen von schlaf |
| CA2205919A1 (en) * | 1994-11-23 | 1996-05-30 | Cocensys, Inc. | Androstane and pregnane series for allosteric modulation of gaba receptor |
| WO2006010085A1 (en) * | 2004-07-09 | 2006-01-26 | Roxro Pharma, Inc. | Use of neurosteroids to treat neuropathic pain |
-
2010
- 2010-08-11 JP JP2012524841A patent/JP5745517B2/ja active Active
- 2010-08-11 WO PCT/US2010/045176 patent/WO2011019821A2/en not_active Ceased
- 2010-08-11 EP EP10808696.8A patent/EP2464653B1/en active Active
- 2010-08-11 CN CN201080035660.3A patent/CN102549007B/zh active Active
- 2010-08-11 BR BR112012003085-0A patent/BR112012003085B1/pt active IP Right Grant
- 2010-08-11 US US12/854,226 patent/US8362286B2/en active Active
- 2010-08-11 MX MX2012001728A patent/MX2012001728A/es active IP Right Grant
- 2010-08-11 EA EA201270241A patent/EA024269B1/ru active IP Right Revival
- 2010-08-11 AU AU2010282570A patent/AU2010282570B2/en active Active
- 2010-08-11 ES ES10808696.8T patent/ES2524724T3/es active Active
- 2010-08-11 CA CA2769820A patent/CA2769820C/en active Active
- 2010-08-11 KR KR1020127006429A patent/KR101778603B1/ko active Active
- 2010-08-11 NZ NZ597940A patent/NZ597940A/xx unknown
-
2012
- 2012-01-31 IL IL217857A patent/IL217857A/en active IP Right Grant
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3953429A (en) * | 1970-12-17 | 1976-04-27 | Glaxo Laboratories Limited | Anaesthetic steroids of the androstance and pregnane series |
| US6117994A (en) * | 1994-06-02 | 2000-09-12 | Hoechst Marion Roussel | Intermediates for 16β-methyl steroids |
| WO2007062266A2 (en) * | 2005-11-28 | 2007-05-31 | Marinus Pharmaceuticals | Ganaxolone formulations and methods for the making and use thereof |
Non-Patent Citations (3)
| Title |
|---|
| Substituted 3β-Phenylethynyl Derivatives of 3α-Hydroxy-5α-pregnan-20-one: Remarkably Potent Neuroactive Steroid Modulators of γ-Aminobutyric Acida Receptors;JON E.KAWKINSON et al;《THE JOURANL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS》;19981231;第287卷(第1期);第198-207页 * |
| Synthesis and in Vitro Activity of 3β-Substituted-3α-hydroxypregnan-20-ones: Allosteric Modulators of the GABAa Receptor;Derk J.Hogenkamp et al;《J.Med.Chem.》;19971231;第40卷(第1期);第61-72页 * |
| 加那索酮的合成;何明华等;《中国新药杂志》;20051231;第14卷(第8期);第1025-1028页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| BR112012003085B1 (pt) | 2021-06-01 |
| BR112012003085A2 (pt) | 2020-12-01 |
| MX2012001728A (es) | 2012-06-01 |
| HK1171761A1 (en) | 2013-04-05 |
| KR20120084715A (ko) | 2012-07-30 |
| CA2769820C (en) | 2017-06-27 |
| US8362286B2 (en) | 2013-01-29 |
| EP2464653A2 (en) | 2012-06-20 |
| JP5745517B2 (ja) | 2015-07-08 |
| EA024269B1 (ru) | 2016-09-30 |
| CN102549007A (zh) | 2012-07-04 |
| EA201270241A1 (ru) | 2013-09-30 |
| WO2011019821A2 (en) | 2011-02-17 |
| AU2010282570B2 (en) | 2014-04-24 |
| NZ597940A (en) | 2013-03-28 |
| IL217857A0 (en) | 2012-03-29 |
| CA2769820A1 (en) | 2011-02-17 |
| WO2011019821A3 (en) | 2011-06-16 |
| JP2013501803A (ja) | 2013-01-17 |
| IL217857A (en) | 2016-03-31 |
| ES2524724T3 (es) | 2014-12-11 |
| AU2010282570A1 (en) | 2012-02-23 |
| EP2464653B1 (en) | 2014-10-22 |
| KR101778603B1 (ko) | 2017-09-14 |
| US20110040112A1 (en) | 2011-02-17 |
| EP2464653A4 (en) | 2013-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102549007B (zh) | 3α-羟基,3β-甲基-5α-孕烷-20-酮(加奈索酮)的制备方法 | |
| CN101652142B (zh) | 盐皮质激素受体拮抗剂 | |
| JPH0113719B2 (enExample) | ||
| CN111328332B (zh) | 用于制备胆汁酸类的方法 | |
| CN102164921A (zh) | 长春西汀和阿扑长春胺的制备方法 | |
| JP6100798B2 (ja) | １６−置換型−１７−ケトステロイド類のアルキニル化方法 | |
| JP2021183627A (ja) | １１−メチレンステロイドの製造のための方法および新規な中間体 | |
| JPH07503466A (ja) | 新規ステロイド中間体およびその製造法 | |
| WO2010122096A1 (en) | Process for obtaining fluorometholone and intermediates therefor | |
| HK1171761B (en) | METHOD FOR MAKING 3α-HYDROXY, 3β- METHYL-5α-PREGNAN-20-ONE (GANAXOLONE) | |
| WO2024131056A1 (zh) | Paxlovid和波普瑞韦中间体的合成方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1171761 Country of ref document: HK |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1171761 Country of ref document: HK |